DRRX:NASDAQ

DURECT Corp.

DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development: New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator program. Its drug development expertise is being applied primarily to the fields of pain management, central nervous system disorders, acute organ injury and metabolic diseases such as nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Late-stage development programs include POSIMIR (SABER-bupivacaine) and REMOXY (ORADUR-oxycodone). DURECT's epigenomic regulator program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival.
DRRX:NASDAQ

Expert Comments:

Francois Brisebois, Laidlaw & Company (6/27/18)
"An interesting buying opportunity may present itself for DURECT Corp. as we continue to view its DUR-928 platform as the main value driver and are encouraged by its progress. . .we expect the company to reveal interim data in H2/18. . .we continue to view DURECT as undervalued and are reiterating our Buy rating."

Francois Brisebois, Laidlaw & Company (5/3/18)
"DURECT Corp. reported its Q1/18 last night, mostly in line with expectations. . .with multiple data readouts in oral and four Phase 2a studies of DUR-928, initiation of a topical study in psoriasis and two PDUFA dates with financial implications, 2018 offers many key catalysts. To better reflect the amount of potential data readouts in H2/18 as well as DUR-928's ultimate potential, we are maintaining our Buy rating and raising our price target from $2.50 to $3."

Patrick Dolezal, LifeSci Capital (4/25/18)
"Today, Durect Corp. announced the initiation of dosing of a Phase 2a trial with DUR-928, the lead product candidate in its epigenetic regulator program, for the treatment of alcoholic hepatitis. . .the primary outcome measures focus on safety and pharmacokinetics though assessments of liver function will also be taken. Initial results from this trial are expected later in 2018."

Patrick Dolezal, LifeSci Capital (4/25/18)
"Today, Durect Corp. announced the initiation of dosing of a Phase 2a trial with DUR-928, the lead product candidate in its epigenetic regulator program, for the treatment of alcoholic hepatitis. . .the primary outcome measures focus on safety and pharmacokinetics though assessments of liver function will also be taken. Initial results from this trial are expected later in 2018."

Len Yaffe, Seeking Alpha (3/23/18)
"DURECT Corp. has two upcoming U.S. Food and Drug Administration PDUFA dates that could drive increased interest in its stock, and it will also have initial Phase 2 data on DUR-928 later in 2018. . .I continue to maintain that the current valuation of the stock does not reflect the value creation opportunities that will unfold over the next year. . .there are few stocks with similar upside potential."

Management Q&A: View From the Top
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018.
read more >
Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs.
read more >
Ed Arce, H.C. Wainwright & Co. (3/6/18)
"Given our favorable view on the prospects of DURECT Corp.'s DUR-928 in primary sclerosing cholangitis (PSC) and multiple near-term catalysts, we raise our rating on the company's shares to Buy. . .we believe PSC, as an ultra-orphan disease with no approved therapies, represents a substantial commercial opportunity. . .our new price target is $3.50."

More Expert Comments

Experts Following This Company

Ed Arce, Managing Direction and Senior Research Analyst – H.C. Wainwright & Co.
Francois Brisebois, Healthcare Research Analyst – Laidlaw & Company
Patrick Dolezal – LifeSci Capital
Adam Walsh, Analyst-Healthcare – Stifel
Len Yaffe, Fund Manager, analyst, MD – Stoc*Doc Partners
Grant Zeng, Senior Biotech Analyst – Zacks Investment Research, Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

DURECT Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
DUR-928, in Phase 1, is an Endogenous Small Molecule with Compelling Animal Data
 
Two Late Stage Pain Products Addressing Large Markets
 
Company Holds the WW Rights to DUR-928 and POSIMIR